Fieldview Capital Management LLC Invests $3.74 Million in Royalty Pharma PLC $RPRX

Key Points

• Fieldview Capital Management opened a new position in Royalty Pharma, buying 96,752 shares worth about $3.74 million in the fourth quarter.
• Institutional interest in RPRX remains strong, with hedge funds and other investors owning 54.35% of the company’s shares and several firms adding to or starting positions recently.
• Royalty Pharma posted better-than-expected EPS in its latest quarter, and Wall Street sentiment is broadly positive, with analysts assigning an average Buy rating and a consensus price target of $53.71.

Fieldview Capital Management LLC purchased a new stake in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 96,752 shares of the biopharmaceutical company's stock, valued at approximately $3,738,000.

Other hedge funds have also recently bought and sold shares of the company. Nomura Asset Management Co. Ltd. raised its holdings in Royalty Pharma by 16.2% in the fourth quarter. Nomura Asset Management Co. Ltd. now owns 172,418 shares of the biopharmaceutical company's stock valued at $6,662,000 after buying an additional 24,048 shares during the period. Fideuram Intesa Sanpaolo Private Banking S.P.A. purchased a new position in Royalty Pharma in the fourth quarter valued at approximately $4,923,000. Regal Partners Ltd raised its holdings in Royalty Pharma by 6.7% in the third quarter. Regal Partners Ltd now owns 1,435,126 shares of the biopharmaceutical company's stock valued at $50,631,000 after buying an additional 89,930 shares during the period. Qsemble Capital Management LP purchased a new position in Royalty Pharma in the fourth quarter valued at approximately $2,875,000. Finally, Nordea Investment Management AB raised its holdings in Royalty Pharma by 4.7% in the fourth quarter. Nordea Investment Management AB now owns 812,663 shares of the biopharmaceutical company's stock valued at $31,604,000 after buying an additional 36,664 shares during the period. Hedge funds and other institutional investors own 54.35% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on RPRX shares. Weiss Ratings lowered shares of Royalty Pharma from a "buy (b)" rating to a "buy (b-)" rating in a report on Friday, May 15th. Morgan Stanley raised their price target on shares of Royalty Pharma from $61.00 to $63.00 and gave the company an "overweight" rating in a report on Friday, April 10th. Citigroup raised their price target on shares of Royalty Pharma from $50.00 to $66.00 and gave the company a "buy" rating in a report on Thursday, May 7th. UBS Group lifted their price objective on shares of Royalty Pharma from $51.00 to $57.00 and gave the company a "buy" rating in a research note on Tuesday, April 21st. Finally, Wall Street Zen upgraded shares of Royalty Pharma from a "buy" rating to a "strong-buy" rating in a research note on Saturday, May 9th. Seven analysts have rated the stock with a Buy rating, According to MarketBeat, the company has an average rating of "Buy" and a consensus target price of $53.71.

Royalty Pharma Stock Down 0.8%

Shares of NASDAQ:RPRX opened at $54.87 on Friday. The company has a current ratio of 2.66, a quick ratio of 2.66 and a debt-to-equity ratio of 0.86. The company has a fifty day simple moving average of $51.59 and a 200 day simple moving average of $45.57. The firm has a market cap of $31.60 billion, a PE ratio of 37.33, a price-to-earnings-growth ratio of 1.51 and a beta of 0.43. Royalty Pharma PLC has a 12-month low of $34.08 and a 12-month high of $56.50.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.22 by $0.08. The business had revenue of $630.58 million during the quarter, compared to analyst estimates of $881.69 million. Royalty Pharma had a net margin of 33.88% and a return on equity of 29.25%. On average, equities research analysts anticipate that Royalty Pharma PLC will post 5.05 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th were issued a $0.235 dividend. This represents a $0.94 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date of this dividend was Friday, May 15th. Royalty Pharma's payout ratio is currently 63.95%.

Insiders Place Their Bets

In other Royalty Pharma news, EVP Marshall Urist sold 13,684 shares of Royalty Pharma stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $53.06, for a total value of $726,073.04. Following the completion of the transaction, the executive vice president owned 31,881 shares of the company's stock, valued at $1,691,605.86. The trade was a 30.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gregory Norden sold 3,045 shares of Royalty Pharma stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $53.00, for a total transaction of $161,385.00. Following the completion of the transaction, the director directly owned 191,803 shares of the company's stock, valued at approximately $10,165,559. This represents a 1.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 199,185 shares of company stock valued at $10,082,926 over the last 90 days. 18.84% of the stock is owned by company insiders.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company's transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.